Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MW5311 in Relapsed/Refractory AML, CMML, and MM
NCT07914556Phase 1Recruiting
- Sponsor
- Mabwell
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of 6MW5311 in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and multiple myeloma (MM) (2 arms), sponsored by Mabwell. Primary endpoints: Number of participants with dose-limiting toxicities at 28 days and Number of participants with treatment-emergent adverse events at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
6MW5311
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07914556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914556.